Compare CARS & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CARS | ARMP |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.1M | 383.7M |
| IPO Year | 2017 | 1996 |
| Metric | CARS | ARMP |
|---|---|---|
| Price | $10.09 | $12.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $16.00 | $15.00 |
| AVG Volume (30 Days) | ★ 1.4M | 38.2K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $723,239,000.00 | N/A |
| Revenue This Year | $2.97 | N/A |
| Revenue Next Year | $2.48 | N/A |
| P/E Ratio | $31.58 | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $7.40 | $1.17 |
| 52 Week High | $13.97 | $13.75 |
| Indicator | CARS | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 68.89 | 67.01 |
| Support Level | $7.88 | $5.14 |
| Resistance Level | $13.66 | $13.75 |
| Average True Range (ATR) | 0.38 | 1.17 |
| MACD | 0.28 | 0.31 |
| Stochastic Oscillator | 92.72 | 96.01 |
Cars.com Inc is an audience-powered and data-driven technology platform that simplifies buying and selling cars. The flagship Cars.com marketplace connects consumers to dealerships across the U.S., powering the car-buying experience with artificial intelligence (AI) shopping tools, vehicle reviews and content. Its ecosystem of products enables dealers and OEMs to sell more cars by leveraging the marketplace, dealer websites, trade and appraisal tools and proprietary in-market media solutions. The platform provides shoppers with data, resources and digital tools to make informed buying decisions and connect with automotive retailers. The Company also provides dealerships and OEMs with solutions and data-driven intelligence to reach and influence its 26 million monthly shoppers.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.